{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T08:05:20Z","timestamp":1779869120145,"version":"3.53.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jmii.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:19:00Z","timestamp":1775517540000},"page":"285-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations and guidance for pneumococcal vaccination for adults in Taiwan"],"prefix":"10.1016","volume":"59","author":[{"given":"I-Fan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-0815","authenticated-orcid":false,"given":"Wei-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chia","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-1260","authenticated-orcid":false,"given":"Ping-Feng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-0752","authenticated-orcid":false,"given":"Chia-Hsiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7973-2574","authenticated-orcid":false,"given":"Miao-Chiu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Chang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-2116","authenticated-orcid":false,"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2825","authenticated-orcid":false,"given":"Ping-Ing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Siang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1919","authenticated-orcid":false,"given":"Ming-Han","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen-Sheue","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-2414","authenticated-orcid":false,"given":"Susan Shin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019","volume":"400","author":"Ikuta","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijid.2023.04.003","article-title":"Determinants of poor clinical outcome in patients with influenza pneumonia: a systematic review and meta-analysis","volume":"131","author":"Arranz-Herrero","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237871","article-title":"Longitudinal investigation of nasopharyngeal pneumococcal carriage in early childhood: the PATCH birth cohort study","volume":"15","author":"Tsai","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2026.04.001_bib4","series-title":"Quarterly report on invasive pneumococcal disease (IPD)","year":"2025"},{"key":"10.1016\/j.jmii.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7774\/cevr.2015.4.2.121","article-title":"Pneumococcal disease and use of pneumococcal vaccines in Taiwan","volume":"4","author":"Wei","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.jmii.2026.04.001_bib6","author":"Chiang"},{"key":"10.1016\/j.jmii.2026.04.001_bib7","author":"Ryan Gierke"},{"key":"10.1016\/j.jmii.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.otohns.2006.11.039","article-title":"Threshold shift: effects of cochlear implantation on the risk of pneumococcal meningitis","volume":"136","author":"Wei","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jmii.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1128\/CMR.00009-08","article-title":"Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis","volume":"21","author":"Tebruegge","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jmii.2026.04.001_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jmii.2026.04.001_bib13","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2016.044","article-title":"Influenza and pneumococcal vaccination in hematological malignancies: a systematic review of efficacy, effectiveness, and safety","volume":"8","author":"La Torre","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.2147\/COPD.S140378","article-title":"Pneumococcal vaccination and chronic respiratory diseases","volume":"12","author":"Froes","year":"2017","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jmii.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"Van Aalst","year":"2018","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/cid\/ciz739","article-title":"Early impact of 13-Valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-united states","volume":"70","author":"Ahmed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijid.2020.07.013","article-title":"Risk of invasive pneumococcal disease in patients with asplenia\/hyposplenism: a nationwide population-based study in Korea, 2009-2018","volume":"98","author":"Kang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00408-020-00349-y","article-title":"Incidence and risk of pneumococcal pneumonia in adults with distinct underlying medical conditions: a population-based study","volume":"198","author":"Vila-Corcoles","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jmii.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/cid\/ciab651","article-title":"Chronic disease and immunosuppression increase the risk for nonvaccine serotype pneumococcal disease: a nationwide population-based study","volume":"74","author":"Naucler","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2350093","article-title":"The effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly colorectal cancer long-term survivors: a population-based exact-matched cohort study","volume":"20","author":"Lee","year":"2024","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2025.2489659","article-title":"Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations","volume":"24","author":"Radcliffe","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jmii.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jamda.2016.11.010","article-title":"Pneumococcal vaccination guidance for post-acute and long-term care settings: recommendations from AMDA's infection advisory committee","volume":"18","author":"Nace","year":"2017","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jmii.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.rmed.2005.02.026","article-title":"Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan","volume":"99","author":"Lauderdale","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jmii.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7774\/cevr.2024.13.2.91","article-title":"A narrative review of genomic characteristics, serotype, immunogenicity, and vaccine development of Streptococcus pneumoniae capsular polysaccharide","volume":"13","author":"Sari","year":"2024","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.jmii.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10156-013-0601-1","article-title":"Pneumococcal vaccine and opsonic pneumococcal antibody","volume":"19","author":"Song","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jmii.2026.04.001_bib27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jinf.2022.04.022","article-title":"Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: a multi-center clinical microbiological study after PCV13 implementation","volume":"84","author":"Chen","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmii.2022.08.018","article-title":"Antimicrobial susceptibility and serotype replacement of Streptococcus pneumoniae in children before and after PCV13 introduction in Taiwan","volume":"56","author":"Huang","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/14760584.2024.2404636","article-title":"Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy","volume":"23","author":"Fletcher","year":"2024","journal-title":"Expet Rev Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib30","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-Valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the journal of clinical epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jmii.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.jmii.2026.04.001_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083867","article-title":"Core GRADE 7: principles for moving from evidence to recommendations and decisions","volume":"389","author":"Guyatt","year":"2025","journal-title":"Br Med J"},{"key":"10.1016\/j.jmii.2026.04.001_bib37","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/cid\/ciy1127","article-title":"Successful control of Streptococcus pneumoniae 19A replacement with a Catch-up primary vaccination program in Taiwan","volume":"69","author":"Lu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jfma.2019.01.020","article-title":"Control and prevention of invasive pneumococcal disease in Taiwan: current achievements and future challenges","volume":"118","author":"Su","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jmii.2026.04.001_bib39","author":"Chiang"},{"key":"10.1016\/j.jmii.2026.04.001_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.557404","article-title":"Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in Pre- and Post- PCV7\/13 eras, Taiwan, 2002-2018","volume":"11","author":"Wu","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jmii.2026.04.001_bib41","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2009.06.091","article-title":"National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential","volume":"27","author":"Hsieh","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.vaccine.2014.04.061","article-title":"National surveillance of invasive pneumococcal diseases in Taiwan, 2008\u20132012: differential temporal emergence of serotype 19A","volume":"32","author":"Chiang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jmii.2012.08.011","article-title":"Comparison of invasive pneumococcal disease caused by serotype 19A and non-19A pneumococci in children: more empyema in serotype 19A invasive pneumococcal disease","volume":"47","author":"Lai","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s15010-024-02426-3","article-title":"Clinical features and immune memory of breakthrough infection in children after age-appropriate 13-valent pneumococcal conjugate vaccination in Taiwan","volume":"53","author":"Chen","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2026.04.001_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12879-020-05721-0","article-title":"Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan","volume":"21","author":"Su","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jmii.2023.01.013","article-title":"Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: a multicenter observational study","volume":"56","author":"Aydin","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1086\/529142","article-title":"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory","volume":"46","author":"De Roux","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib49","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1086\/523583","article-title":"A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients","volume":"45","author":"Kumar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14760584.2021.1889374","article-title":"Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature","volume":"20","author":"Cripps","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jmii.2026.04.001_bib51","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.vaccine.2003.10.030","article-title":"Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study","volume":"22","author":"Hung","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-Valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2026.04.001_bib53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/pathogens12050732","article-title":"Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults","volume":"12","author":"Farrar","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.jmii.2026.04.001_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","article-title":"Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence","volume":"20","author":"Niederman","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jmii.2026.04.001_bib55","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.vaccine.2015.04.068","article-title":"The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program","volume":"33","author":"Tsai","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib56","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2026.04.001_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","article-title":"A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults)","volume":"5","author":"Patterson","year":"2016","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.jmii.2026.04.001_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126543","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults","volume":"44","author":"Hsiao","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib59","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","article-title":"Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/jiu631","article-title":"Immunogenicity and safety of 13-Valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine","volume":"212","author":"Glesby","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib61","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1080\/21645515.2020.1735224","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence","volume":"16","author":"Chilson","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib62","article-title":"Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-Cell therapy","volume":"29","author":"Lee","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jmii.2026.04.001_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056986","article-title":"Association between PCV13 pneumococcal vaccination and risk of hospital admissions due to pneumonia or sepsis among patients with haematological malignancies: a single-centre retrospective cohort study in Israel","volume":"12","author":"Draliuk","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jmii.2026.04.001_bib64","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults age \u226550 years: a randomized phase III trial (PNEU-PATH)","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000003126","article-title":"Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV","volume":"36","author":"Mohapi","year":"2022","journal-title":"Aids"},{"key":"10.1016\/j.jmii.2026.04.001_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2177066","volume":"19","author":"Hammitt","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib67","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/cid\/ciad349","article-title":"A phase 3, randomized, double-blind, comparator-controlled study to evaluate safety, tolerability, and immunogenicity of V114, a 15-Valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM)","volume":"77","author":"Wilck","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib68","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib69","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.vaccine.2022.06.041","article-title":"Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A","volume":"40","author":"Hao","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib70","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.vaccine.2024.01.004","article-title":"A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adult \u2265 60 years of age in Japan, South Korea, and Taiwan","volume":"42","author":"Haranaka","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib71","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf695.1615","article-title":"Real-world effectiveness of 20-Valent pneumococcal conjugate vaccine among adults 65-74, 75-84, and \u226585 years of age in the United States","volume":"13","author":"Miles","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13040341","article-title":"A phase 3 randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal vaccine, compared with PPSV23, in adults \u226550 years of age (STRIDE-10)","volume":"13","author":"Jotterand","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.jmii.2026.04.001_bib74","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/cid\/ciae383","article-title":"A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (STRIDE-6)","volume":"79","author":"Scott","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib75","article-title":"Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 Western European countries and the United States","volume":"8","author":"Noharet-Koenig","year":"2023","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.jmii.2026.04.001_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","article-title":"Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands","volume":"22","author":"De Boer","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jmii.2026.04.001_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the advisory committee on immunization practices - united States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jmii.2026.04.001_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jmii.2026.04.001_bib79","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib80","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib81","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.vaccine.2022.12.060","article-title":"Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-na\u00efve adults aged \u2265 65 years: comparison of booster effects based on intervals of 0.5 and 1.0 year","volume":"41","author":"Azuma","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib82","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1080\/21645515.2021.1888621","article-title":"Sequential administration of prevnar 13\u2122 and PNEUMOVAX\u2122 23 in healthy participants 50 years of age and older","volume":"17","author":"Buchwald","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib83","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3899\/jrheum.161407","article-title":"Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmii.2026.04.001_bib84","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1080\/21645515.2018.1438091","article-title":"Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis","volume":"14","author":"Bahuaud","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the european myeloma network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jmii.2026.04.001_bib86","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2020.05.024","article-title":"Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: results of a prospective clinical study","volume":"38","author":"Stoma","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib87","series-title":"Prevention and treatment of cancer-related infections. Version 1.2025","year":"2025"},{"key":"10.1016\/j.jmii.2026.04.001_bib88","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.cmi.2022.12.007","article-title":"Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial","volume":"29","author":"Okinaka","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib89","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on infections in leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/civ287","article-title":"Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged \u22652 years: an open-label study","volume":"61","author":"Cordonnier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib91","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.26493","article-title":"Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation","volume":"97","author":"Garcia Garrido","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmii.2026.04.001_bib92","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.vaccine.2018.08.069","article-title":"Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence","volume":"36","author":"Dendle","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib93","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jmii.2026.04.001_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13343","article-title":"A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients","volume":"22","author":"Eriksson","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib95","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/vaccines11101611","article-title":"Vaccination recommendations in solid organ transplant adult candidates and recipients","volume":"11","author":"Vigan\u00f2","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jmii.2026.04.001_bib96","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s15010-023-02054-3","article-title":"Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients","volume":"51","author":"M\u00fclling","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2026.04.001_bib97","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmii.2026.04.001_bib98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2026.04.001_bib99","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jmii.2026.04.001_bib100","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib101","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/21645515.2018.1456611","article-title":"Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly","volume":"14","author":"Kawakami","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib102","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/21645515.2018.1533777","article-title":"Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial","volume":"15","author":"Thompson","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1976581","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged \u226550 years: a randomized phase 3 trial (PNEU-FLU)","volume":"18","author":"Severance","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jmii.2026.04.001_bib104","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.vaccine.2022.11.046","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: a phase 3 randomized trial","volume":"41","author":"Cannon","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib105","volume":"15","author":"Bai","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jmii.2026.04.001_bib106","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged \u226565 years","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127514","article-title":"A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older","volume":"62","author":"Omole","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib108","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib109","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1016\/j.vaccine.2023.05.002","article-title":"Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults \u226565 years old","volume":"41","author":"Fitz-Patrick","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib110","article-title":"Safety, tolerability, and immunogenicity of the pneumococcal vaccines PPSV23 or PCV15 Co-Administered with a booster dose of mRNA-1273 SARS-CoV-2 vaccine in healthy adults \u226550 years of age","volume":"13","author":"Omole","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.jmii.2026.04.001_bib111","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/ciad746","article-title":"Age-specific resurgence in invasive pneumococcal disease incidence in the COVID-19 pandemic era and its association with respiratory virus and pneumococcal carriage dynamics: a time-series analysis","volume":"78","author":"Rybak","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib112","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550 years of age: a randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib113","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jinf.2021.12.033","article-title":"The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged \u226550 years: a randomized trial","volume":"84","author":"Min","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib114","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12879-018-3479-9","article-title":"Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in \u2265 50-year-old adults","volume":"18","author":"Song","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib115","series-title":"Menactra\u00ae (meningococcal groups A, C, Y, W-135 polysaccharide-diphtheria toxoid conjugate vaccine) full prescribing information, FDA package insert","year":"2018"},{"key":"10.1016\/j.jmii.2026.04.001_bib116","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cmi.2023.08.006","article-title":"Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial","volume":"29","author":"Riekkinen","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2026.04.001_bib117","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s12879-016-2040-y","article-title":"Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review","volume":"16","author":"Remschmidt","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2026.04.001_bib118","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.vaccine.2016.04.021","article-title":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the vaccine adverse event reporting system (VAERS), 1990-2013","volume":"34","author":"Miller","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib119","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52597","article-title":"Cardiovascular, neurological, and immunological adverse events and the 23-Valent pneumococcal polysaccharide vaccine","volume":"7","author":"Yoon","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jmii.2026.04.001_bib120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.vaccine.2019.01.014","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: a systematic review and meta-analysis","volume":"37","author":"Vadlamudi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jmii.2026.04.001_bib121","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jval.2011.11.013","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach","volume":"15","author":"Wu","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jmii.2026.04.001_bib122","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jfma.2011.10.006","article-title":"Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis","volume":"112","author":"Wu","year":"2013","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118226000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118226000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:29:30Z","timestamp":1779866970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118226000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1684118226000460"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2026.04.001","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations and guidance for pneumococcal vaccination for adults in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}